Minerva Neurosciences, Inc. (NERV) Can’t Be More Risky. The Stock Formed a Wedge Down Pattern

December 7, 2017 - By Clifton Ray

The stock of Minerva Neurosciences, Inc. (NERV) formed a down wedge with $5.10 target or 9.00 % below today’s $5.60 share price. The 6 months wedge indicates high risk for the $216.72M company. If the $5.10 price target is reached, the company will be worth $19.51 million less.
Falling wedges are poor performers for bullish breakouts and are tricky moments to trade. Investors must be aware that the break even failure rate for up or down breakouts is: 11% and 15%. The average rise is 32% and the decline is 15%. The falling wedges has high throwback and pullback rate: 56%, 69% and the percent of wedges meeting target is not very high.

The stock increased 7.69% or $0.4 during the last trading session, reaching $5.6. About 150,990 shares traded. Minerva Neurosciences, Inc. (NASDAQ:NERV) has risen 56.56% since December 8, 2016 and is uptrending. It has outperformed by 39.86% the S&P500.

Analysts await Minerva Neurosciences, Inc. (NASDAQ:NERV) to report earnings on March, 12. They expect $-0.43 EPS, down 59.26 % or $0.16 from last year’s $-0.27 per share. After $-0.28 actual EPS reported by Minerva Neurosciences, Inc. for the previous quarter, Wall Street now forecasts 53.57 % negative EPS growth.

Minerva Neurosciences, Inc. (NASDAQ:NERV) Ratings Coverage

Among 3 analysts covering Minerva Neurosciences (NASDAQ:NERV), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Minerva Neurosciences had 5 analyst reports since March 9, 2016 according to SRatingsIntel. As per Thursday, June 22, the company rating was maintained by Jefferies. The firm earned “Buy” rating on Friday, May 27 by Jefferies. Jefferies reinitiated it with “Buy” rating and $10 target in Thursday, May 12 report. JMP Securities maintained it with “Market Outperform” rating and $10 target in Wednesday, March 9 report. Citigroup initiated the stock with “Buy” rating in Friday, September 1 report.

More notable recent Minerva Neurosciences, Inc. (NASDAQ:NERV) news were published by: Globenewswire.com which released: “American Journal of Psychiatry Publishes Minerva Neurosciences’ MIN-101 Phase …” on July 31, 2017, also Globenewswire.com with their article: “Minerva Neurosciences, Inc. to Offer Common Shares” published on February 28, 2017, Seekingalpha.com published: “Minerva Neurosciences’ (NERV) CEO Remy Luthringer on Q2 2017 Results …” on August 05, 2017. More interesting news about Minerva Neurosciences, Inc. (NASDAQ:NERV) were released by: Seekingalpha.com and their article: “A Deep Dive Into Minerva Neurosciences’ Pipeline” published on May 16, 2017 as well as Fool.com‘s news article titled: “Why Minerva Neurosciences Inc. Fell 31.1% in July” with publication date: August 07, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.